Anatara Lifesciences rose by 20 per cent over the five trading days after news that the company had been awarded a Japanese patent for its irritable bowel syndrome medicine called GaRP (Gastrointestinal ReProgramming).

The patent further consolidates the commercial position for the company’s IP, Anatara Lifesciences said.

The granted patent is valid in Japan for 20 years from 9 October 2020, and follows previously announced similar grants for Hong Kong, Australia and the EU.

Anatara Lifesciences says the commercial opportunity for non-prescription products for gastrointestinal disorders and IBS is USD$8 billion in the US alone.

You might like

Business

Optus-led consortium to launch Adelaide-made satellite by 2028

Sponsored

Inside the efforts to decarbonise our fishing industry

The company also progressed its anti-obesity project at the University of Newcastle.

There, Anatara is designing an oral complementary medication to assist with weight reduction and sustaining weight control.

The news put Anatara in the number three position on the Winners list last week, below Jade Gas Holdings and Fortifai.

News was light more broadly among both the Winners and the Losers, Baker Young Analysts said.

But the broader market had a modestly negative reaction to the Reserve Bank’s decision to leave interest rates on hold.

Markets were 90 per cent priced for a 25-basis point cut, but given the likelihood of a cut in August, the shock to the stock exchange wasn’t too dramatic, analysts said

The full list of Winners and Losers for the week ended 11 July:

Data via Baker Young Limited analysts.